Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
8
×
life sciences
national blog main
clinical trials
fda
boston top stories
national top stories
san francisco blog main
eli lilly
indiana blog main
indiana top stories
san francisco top stories
boston
deals
europe blog main
europe top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
amgen
avapritinib
blueprint medicines
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
genentech
investing
medullary thyroid cancer
non-small cell lung cancer
novartis
pralsetinib
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
What
drug
8
×
fda
8
×
approval
medicines
cancer
won
approved
blueprint
designed
friday
loss
marketing
medicine
new
ret
therapeutics
therapy
treat
weight
acquire
acute
address
addresses
affects
agency
agreed
aimmune
alkermes
allergy
americans
antipsychotic
approves
awarded
benefits
billion
brings
candidate
carries
cash
causes
Language
unset
8
×
Current search:
drug
×
biotech
×
unset
×
" boston blog main "
×
fda
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds